RICHARD KIRKPATRICK: Open Payments
NPI 1851377030 · LONGVIEW, WA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,910 in 136 payments from 40 companies in 2025. Trend: 2023 $2,517 · 2024 $2,876 · 2025 $2,910
Food & beverage: $2,860Long term medical supply or device loan: $50
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 25 | $560 |
| Novartis Pharmaceuticals Corporation | 9 | $247 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 14 | $188 |
| Corcept Therapeutics | 7 | $151 |
| PFIZER INC. | 5 | $109 |
| Lundbeck LLC | 5 | $107 |
| Axsome Therapeutics, Inc. | 3 | $99 |
| Lilly USA, LLC | 5 | $99 |
| Otsuka America Pharmaceutical, Inc. | 4 | $86 |
| Abbott Laboratories | 3 | $84 |
Products named: LEQVIO, AIRSUPRA, REXULTI, BREZTRI, XIFAXAN, Korlym, Auvelity, Kerendia.
Industry payments across WA — which companies pay providers there.
